data + articles · 1 listed
newest 2009spec sheet11 rows
4-PMPD is an obscure research chemical that vendor and reference sources identify with 4-benzylpiperidine, also named 4-(phenylmethyl)piperidine [1]. 4-Benzylpiperidine is a documented monoamine releasing agent that preferentially releases dopamine over serotonin and has been studied as a candidate agonist medication for cocaine dependence [1]. Because the mapping of the trade name 4-PMPD to 4-benzylpiperidine rests on vendor and encyclopedic identification rather than peer-reviewed confirmation of this exact product, the identity should be treated as probable but not definitively verified.
- As 4-benzylpiperidine, produces rapid dopamine-selective stimulation in animal models
- Studied preclinically as a candidate agonist-type medication for cocaine dependence
- Elevated heart rate and blood pressure
- Anxiety or agitation
- Insomnia
- Appetite suppression
Overview
The best-characterized compound matching the 4-PMPD label is 4-benzylpiperidine, which appears in the addiction-pharmacology literature as one of several dopamine-selective monoamine releasers evaluated in nonhuman primates. In a study of releasers with roughly 20 to 48 fold selectivity for dopamine over serotonin, 4-benzylpiperidine substituted for cocaine in a drug-discrimination assay and, notably, had the most rapid onset and shortest duration of action among the compounds tested [1].
Beyond this line of preclinical work, dedicated literature on a consumer product called 4-PMPD is essentially absent, and community discussion treats it as a research-material curiosity rather than an established nootropic. There are no human efficacy or safety studies on the branded material. Anyone handling it should recognize that its pharmacology is inferred from 4-benzylpiperidine research and that its short, dopamine-driven action carries the stimulant risks common to this class.
- The compound most likely behind the 4-PMPD label, 4-benzylpiperidine, was studied not to cause a high but to explore whether a dopamine-selective releaser could reduce cocaine self-administration.
- Among the releasers tested in that work, 4-benzylpiperidine stood out for having the fastest onset and shortest duration of action.
Mechanism
If, as reported, 4-PMPD corresponds to 4-benzylpiperidine, its mechanism is that of a substrate-type monoamine releaser that promotes efflux of and, to a lesser extent, and , with a marked preference for dopamine release [1]. This -selective releasing action, together with a rapid onset and short duration, produces cocaine-like discriminative effects in animals while being explored for its potential to blunt cocaine self-administration [1].
receptor fingerprint
/ monoamine releaseSubstrate-type releaser (dopamine-preferring)
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
4-PMPD has no established human safety data. As a dopamine-preferring monoamine releaser, it would be expected to carry the risks typical of stimulants, including elevated heart rate and blood pressure, anxiety or agitation, insomnia and appetite suppression, with abuse potential given its cocaine-like profile in animals. Its short duration could encourage repeated dosing. It is an unapproved research chemical sold for laboratory use only and is not intended for human consumption. Identity and purity should not be assumed without a certificate of analysis.
History
4-Benzylpiperidine has appeared in medicinal-chemistry and addiction-pharmacology research as part of efforts to develop dopamine-selective releasers as candidate treatments for stimulant-use disorders. Its emergence as the grey-market product 4-PMPD is a more recent development driven by research-chemical vendors, and the branded material has little independent history or documentation of its own.
Reputation
4-PMPD is a fringe research chemical with scant following. Community commentary tends to regard it as a laboratory curiosity or collector item rather than a practical nootropic, reflecting both the thin evidence base and the caution warranted by a short-acting, dopamine-releasing stimulant.
Subjective profileweighing the evidence above
Not worth it. The name does not even map reliably to a confirmed molecule, and the best guess identity is a short-acting, dopamine-preferring releaser with cocaine-like properties in animals, no human data at all, and a duration short enough to invite redosing.
Resources
This entry is here for reference.
Research
- 1.Selective suppression of cocaine- versus food-maintained responding by monoamine releasers in rhesus monkeys: benzylpiperazine, (+)phenmetrazine, and 4-benzylpiperidine.
1 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
What is 4-PMPD chemically?
Vendor and reference sources identify it with 4-benzylpiperidine (4-(phenylmethyl)piperidine), a dopamine-selective monoamine releaser. This identification is probable but has not been independently confirmed for the exact product, so treat it with caution.
Is 4-PMPD safe or approved?
No. It is an unapproved research chemical with no human safety data and a stimulant profile that implies abuse and cardiovascular risk. It is sold for laboratory research only.
Adverse effects
- Elevated heart rate and blood pressure
- Anxiety or agitation
- Insomnia
- Appetite suppression
Notes and cautions
- Abuse potential